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THE DIABETES PREVENTION PROGRAM
RESEARCH GROUP
OBJECTIVEdToinvestigatetheassociationbetweenvitaminDstatus,assessedbyplasma25-
hydroxyvitamin D, and risk of incident diabetes.
RESEARCH DESIGN AND METHODSdProspective observational study with a mean
follow-up of 2.7 years in the Diabetes Prevention Program (DPP), a multicenter trial comparing
different strategies for prevention of diabetes in patients with prediabetes. We assessed the
association between plasma 25-hydroxyvitamin D, measured repeatedly during follow-up,
and incident diabetes in the combined placebo (n = 1,022) and intensive lifestyle (n =1 , 0 1 7 )
randomizedarmsoftheDPP.Variablesmeasuredatmultiplestudytimepoints(25-hydroxyvitamin
D, BMI, and physical activity) entered the analyses as time-varying “lagged” covariates, as the
mean of the previous and current visits at which diabetes status was assessed.
RESULTSdAfter multivariate adjustment, including for the DPP intervention, participants in
the highest tertile of 25-hydroxyvitamin D (median concentration, 30.1 ng/mL) had a hazard
ratio of 0.72 (95% CI 0.56–0.90) for developing diabetes compared with participants in the
lowest tertile (median concentration, 12.8 ng/mL). The association was in the same direction in
placebo (0.70; 0.52–0.94) versus lifestyle arm (0.80; 0.54–1.17).
CONCLUSIONSdHigher plasma 25-hydroxyvitaminD, assessed repeatedly, wasassociated
withlowerriskofincidentdiabetesinhigh-riskpatients,afteradjustingforlifestyleinterventions
(dietary changes, increased physical activity, and weight loss) known to decrease diabetes risk.
Becauseoftheobservationalnatureofthestudy,thepotentialassociationbetweenvitaminDand
diabetes needs to be conﬁrmed in intervention studies.
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T
heincidenceofdiabetesisincreasing
at an alarming rate both nationally
and worldwide, with 1.9 million new
cases diagnosed in 2010 in the U.S. alone
(1).Nearly9outof10newcasesaredueto
type 2 diabetes. In clinical trials, lifestyle
changeshaveprovedsuccessfulatlowering
risk of the disease (2,3). In the Diabetes
Prevention Program (DPP), intensive life-
style intervention resulting in weight loss
reducedtherisk ofincidenttype2diabetes
in adults at increased risk by 58% (2).
However, long-term weight maintenance
in the clinical setting has proved elusive.
Moreover, even after successful weight loss,
there is still signiﬁcant residual risk (2,3).
Recently, evidence has emerged to
support the hypothesis that altered vita-
min D homeostasis may play a role in the
development of type 2 diabetes (4). A po-
tentialrole ofvitaminDintype 2diabetes
is suggested by cross-sectional studies
showing that low blood concentration of
25-hydroxyvitamin D is associated with
impaired glucose tolerance and diabetes
(5,6). Results from longitudinal observa-
tional studies ontheassociation between vi-
taminDstatusandtype2diabetessupporta
potentiallink;however,thesestudieshave
assessed blood 25-hydroxyvitamin Donly
once at baseline, which may introduce
bias(7–15).Theresultsfromsmallclinical
trials and post hoc analyses of larger trials
on the effect of vitamin D supplementa-
tion on glycemic outcomes have been in-
consistent (16–23). The 2011 Institute of
Medicine(IOM)DietaryReferenceIntakes
for Calcium and Vitamin D report con-
cluded that the evidence for a potential
role of vitamin D in extraskeletal out-
comes,includingtype2diabetes,isincon-
clusive, and the report recommended a
blood 25-hydroxyvitamin D level .20
ng/mL as sufﬁcient for the majority of
the population in North America (24).
The DPP cohort, representing a large
multiracial sample of U.S. adults at high
risk for development of diabetes, pro-
vides a unique opportunity to study the
association between vitamin D status and
risk of incident diabetes. The present
ancillary study consisted of assessing
plasma 25-hydroxyvitamin D concentra-
tions in stored samples from the DPP
cohort atmultiplestudy time points,with
the purpose of determining the association
between vitamin D status, as assessed by
plasma 25-hydroxyvitamin D, and the risk
of incident diabetes. The large size of the
cohortalsoallowstestingofwhetherhigher
concentrations of 25-hydroxyvitamin D
than those recommended in the 2011
IOMreportmayprovideadditionalbeneﬁt.
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ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS
Study participants
The DPP was a randomized, controlled
clinical trial from 1996to 2001at 27 sites
in the U.S., comparing the effects of inten-
sive lifestyle intervention, metformin, or
placebo on the development of diabetes in
adults at high risk for the disease. The
eligibility criteria, design, and methods of
the DPP have been described in detail
elsewhere(2).Inbrief,inclusioncriteriain-
cluded age $25 years, BMI $24 kg/m
2
($22 kg/m
2 in Asian Americans), fasting
plasma glucose between 5.3 and 6.9
mmol/L (95–125 mg/dL) (#6.9 mmol/L
for American Indian sites), and plasma
glucose between 7.8 and 11 mmol/L
(140–199 mg/dL) after a 75-g oral glucose
tolerance test. The primary exclusion was
any medication known to alter glucose tol-
erance. The Institutional Review Board at
each site approved the protocol, and all
participants gave written informed con-
sent. The Tufts University Institutional Re-
view Board approved the present ancillary
observational study.
All participants were given standard
advice on healthy diet and physical activ-
ity before randomization to one of three
arms: intensive program of lifestyle mod-
iﬁcation (aiming to achieve a weight re-
duction of at least 7% of initial body
weight), standard lifestyle recommenda-
tionsplusmetformin,orstandardlifestyle
recommendations plus placebo (2). The
present observational study was conduc-
ted among participants randomized to
two arms, the intensive lifestyle (n =
1,079) and placebo (standard lifestyle,
n = 1,082). The metformin arm was ex-
cluded to minimize the cost associated
with measurement of 25-hydroxyvitamin
D. Also, 122 participants were excluded
because of lack of consent for ancillary
studies (n = 120), or no available specimen
for measurement of 25-hydroxyvitamin
D at baseline or 6-month follow-up visits
(n = 2). After exclusions, 2,039 partici-
pantswereincludedintheinitialmultivar-
iate analyses that included age, sex, and
BMI as covariates, and 2,002 participants
with complete data for all covariates were
included in the additional multivariate
analyses.
Measurement of plasma
25-hydroxyvitamin D concentration
Plasma 25-hydroxyvitamin D concentra-
tion was measured in samples stored at
2708Cfromthebaseline,6-month,1-year,
2-year,3-year,and4-yearfollow-upvisits.
Stability of vitamin D metabolites during
transport and long-term freezing has been
documented previously (25,26). Plasma
25-hydroxyvitamin D was measured at
the Metabolic Laboratory at Tufts Medical
Centerbyliquidchromatography,tandem
mass spectrometry (LC/MS/MS) (Waters
ACQUITYUPLCwithTQDtriplequadru-
polemassspectrometer),certiﬁedthrough
the National Institute of Standards and
Technology (NIST) vitamin D quality as-
surance program (27). In the most recent
testing, correlation with the NIST external
standard for total 25-hydroxyvitamin D
was 0.994.
Ascertainment of incident diabetes
The primary DPP outcome, development
of diabetes, was assessed using strict labo-
ratory criteria, according to the protocol
b a s e do no r a lg l u c o s e( 7 5 - g )t o l e r a n c e
testing performed annually and fasting
plasma glucose performed semiannually
orwhensymptomsconsistentwithhyper-
glycemia occurred (2,28). The diagnosis
required conﬁrmation by repeat testing.
If a participant was started on a diabetes
medication by their physician, they were
asked to stop the medication and return
for glucose testing to conﬁrm the diagno-
sis of diabetes.
Assessment of potential confounders
and laboratory assessment
The self-reported level of leisure physical
activity was assessed annually with the
modiﬁable activity questionnaire and ex-
pressed as the average metabolic equiva-
lent (MET-hours) per week for the
previous year (2). Usual daily nutrient in-
take during the previous year was as-
sessed at baseline and at the 1-year
follow-upvisitswiththeuseofamodiﬁed
versionoftheBlockfood-frequencyques-
tionnaire, and calcium intake was esti-
mated as described previously (29). Data
on vitamin D intake were not available.
Standardized interviewer-administered
questionnaires were used annually to ob-
tain self-reported data on personal med-
ical history, smoking, medications,
alcohol use, and family medical history.
Self-reported race/ethnicity was classiﬁed
according to the 1990 U.S. Census ques-
tionnaire. Weight was measured using a
standard calibrated scale, height was mea-
sured with a standard stadiometer, and
BMI was calculated (kg/m
2). Hyperten-
sion was deﬁned as blood pressure
.140/90mmHgoruseofantihypertensive
medication. Fasting blood was obtained
and processed according to standardized
procedures. Measurement methods for
hemoglobin A1c, glucose, C-reactive pro-
tein, and creatinine have been described
previously (2). To adjust for sun expo-
sure variability at each DPP study site,
we constructed an ultraviolet index for
each site based on the National Weather
Service data on the monthly means of ul-
travioletindexforeachgeographiclocation
in 1997 (30).
Statistical analysis
Discrete-time proportional hazards mod-
els were used to assess the association
between plasma 25-hydroxvitamin D (in
tertiles) and incident diabetes to account
for interval-censored data (data for dia-
betes status and other variables were
available at 6-month intervals) and time-
dependent covariates (25-hydroxyvitamin
D, BMI, and physical activity). In multi-
variate models, we adjusted for potential
confounders including DPP clinical site
location (categorical variable, 1–27), age
(years), sex (male or female), BMI (kg/m2),
race(white,black,orother),familyhistory
of diabetes (yes or no), history of hyper-
tension at baseline (yes or no), smoking
status at baseline (never, past, or currently
smoking), alcohol and calcium consump-
tion (average of values self-reported
at baseline and 1-year follow-up visits
[g/day and mg/day, respectively]), plasma
C-reactiveprotein(averageofvaluesatbase-
line, 6-month, and 1-year follow-up visits
[mg/dL]), glomerular ﬁltration rate using
the modiﬁcation of diet in renal disease
estimation (31) (average of values at base-
line, 6-month, and 1-year follow-up visits
[mL/min/1.73 m
2]), and physical activity
(MET-hours per week). We also adjusted
for ultraviolet radiation index at the par-
ticipant’sstudysite(meanannualin1997,
90 J/m
2/h). Although adjustment for BMI
and physical activity reﬂect the main ef-
fects of the intensive lifestyle intervention,
to account for additional unmeasured ef-
fects of intervention, all analyses were ad-
justed for treatment assignment (lifestyle
intervention, yes or no). The predictor
(25-hydroxyvitamin D) and other varia-
bles (BMI and physical activity), whose
value was measured at multiple time
points,enteredtheanalysesastime-varying
“lagged” covariates. At each successive
6 - m o n t ht i m ep o i n tw h e nt h eo u t c o m e
(diabetes) was assessed, the value of these
variables wascalculated asthemeanofthe
current and most recent available value
prior to that visit. For the time-varying var-
iables, if either the current or most recent
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Vitamin D and diabetesvalue was missing, we imputed values us-
ing the nonmissing observation (current
or most recent). If both current and most
recent values were missing, then no value
was imputed. Plasma 25-hydroxyvitamin
D exhibited a normal distribution and en-
tered the multivariate models on a contin-
uous scale. For ease of interpretation, we
present results after participants were cat-
egorized into three groups using tertiles
(33.3rd and 66.7th percentiles) of plasma
25-hydroxyvitamin D concentration, as
themeanofthevaluesobtainedatbaseline
and 6-month visits, to account for season
differences. The hazard ratio (HR) of dia-
betesineachofthetwohighesttertileswas
compared with the lowest tertile by ex-
trapolating the per-unit change in esti-
mated hazard from the multivariate
model.
We repeated analyses using the cut
points for plasma 25-hydroxyvitamin D
(as the mean of the values obtained at
baseline and 6-month visits), recommen-
ded for skeletal outcomes by the 2011
IOM report, as follows: ,12 ng/mL (at
risk for deﬁciency, reference group), 12–
19.9 ng/mL (at risk for inadequacy), 20–
29.9 ng/mL (adequacy), 30–49.9 ng/mL
(potentially beneﬁcial), and $50 ng/mL
(potentially harmful) (32). Results are
presented for categories of plasma 25-
hydroxyvitamin D concentration as the
mean of the values obtained at baseline
and 6-month visits, based on cut points
suggested by the IOM Dietary Reference
Intakes for Calcium and Vitamin D report
(24). The results of the HR of diabetes in
each of the higher groups were compared
with the lowest group by extrapolating
the per-unit change in estimated hazard
f r o mt h em u l t i v a r i a t em o d e l .W ea l s o
conducted secondary analyses by tertiles
and IOM cut points using data only from
the baseline visit to compare with the re-
peated measures analyses (33).
We performed subgroup analyses to
examine potential effect modiﬁcation by
the following covariates: treatment arm
(intensive lifestyle or placebo), baseline
age (median cohort value, ,50 or $50
years),sex(maleorfemale),race/ethnicity
(white or nonwhite), baseline BMI (over-
weight, ,30 k/m
2,o ro b e s e ,$30 k/m
2),
and baseline total calcium intake (median
cohort value, ,921 or $921 mg/day).
We checked for the statistical signiﬁcance
of the interaction by using Wald x
2 tests
(34). Regression assumptions of propor-
tional hazards and linearity were assessed
for violations, and all P values were based
on two-sided tests. Statistical analyses
were performed using SAS version 9.2
(SAS, Cary, NC).
RESULTS
Participant characteristics
At baseline, the average age of the cohort
was 51 years and average BMI was 34
kg/m
2 (Table 1). The racial distribution
was diverse: ;57% Caucasian and 21%
African American, and the remaining par-
ticipants were Hispanic American, Asian
American or PaciﬁcI s l a n d e r ,o rN a t i v e
American. The mean self-reported cal-
cium intake was 1,106 mg/dL and plasma
25-hydroxyvitamin D concentration was
21.6 ng/mL. Based on the 2011 IOM re-
port (24), 45% of the cohort had inade-
quate calcium intake at baseline and
approximately half (49%) were at risk
for deﬁciency or inadequacy for vitamin
D( d e ﬁned as 25-hydroxyvitamin D ,20
ng/mL). Participants in the highest tertile
of plasma 25-hydroxyvitamin D concen-
trationweremorelikelyto beolder,male,
Caucasian,andlessoverweight.Theyalso
had lower fasting plasma glucose, hemo-
globinA1c,C-reactiveprotein,andkidney
function; reported higher physical activ-
ity and alcohol and calcium intake; and
were more likely to reside in areas with
higher annual ultraviolet index.
Plasma 25-hydroxyvitamin D
concentration and risk of
incident diabetes
Participants were followed for an average
of 2.7 years (range 0.5–4.5). On a contin-
uous scale, for every 5 ng/mL increase in
25-hydroxyvitamin D, there was a 13%
decrease in the risk of progression to di-
abetes (HR 0.87 [95% CI 0.82–0.92];
Pvalue,0.0001forevery5-unitincrease
in 25-hydroxyvitamin D). When we cate-
gorized participants into tertiles, there
was a 39% lower risk among those in
the highest tertile (median [IQR] 25-
hydroxyvitamin D, 30.1 [27.0–34.5] ng/
mL) compared with those in the lowest
tertile (12.8 [10.4–14.9] ng/mL) after ad-
justment for age and sex (Table 2). Fur-
ther multivariate adjustment for a variety
of diabetes risk factors, including change
in physical activity and BMI during the
study duration, and randomization to
theDPPintervention(lifestyleorplacebo)
attenuated the association, but it re-
mained statistically signiﬁcant (HR 0.72
[95% CI 0.56–0.90], comparing the third
and ﬁrst tertile). Additionally adjusting
for ultraviolet radiation index did not
change the association (data not shown).
Using data from the baseline visit only, the
association between 25-hydroxyvitamin D
anddiabeteswasinthesamedirectionbut
was not statistically signiﬁcant (0.94
[0.75–1.17],comparingthethirdand ﬁrst
tertile).
In analyses by categories of plasma
25-hydroxyvitamin D using cut points
recommended for skeletal outcomes by
the 2011 IOM report (24), participants
with 25-hydroxyvitamin D concentration
.30 ng/mL had a lower risk compared
with those ,30 ng/mL, whereas those in
thehighestcategoryhada60%lowerriskof
developing diabetes compared with partic-
ipantsinthelowestcategory(HR0.40[95%
CI 0.20–0.81], for 25-hydroxyvitamin D
$50 mg/mL vs. ,12 ng/mL) (Table 3).
However,there were very fewparticipants
and diabetes cases in the highest category.
Additionally adjusting for ultraviolet radi-
ation index did not change the association
(data not shown). Using data from the
baseline visit only, the association be-
tween 25-hydroxyvitamin D by IOM cut
points and diabetes was also the same di-
rection but was not statistically signiﬁcant
(0.89[0.47–1.65],for25-hydroxyvitamin
D $50 mg/mL vs. ,12 ng/mL).
Subgroup analyses
The inverse associations between plasma
25-hydroxyvitamin D and incident di-
abetes were generally consistent across all
subgroups (Table 4). The association be-
tween 25-hydroxyvitamin D and diabetes
appeared to be stronger among partici-
pants randomized to placebo compared
with lifestyle (HR 0.70 [95% CI 0.52–
0.94] vs. 0.80 [0.54–1.17], respectively);
among those older than 50 years com-
pared with those younger than 50 years
(0.64 [0.46–0.90] vs. 0.81 [0.57–1.12]);
among women versus men (0.68 [0.50–
0.91] vs. 0.82 [0.55–1.19]); among obese
versus nonobese (0.70 [0.52–0.93] vs.
0.78 [0.50–1.18], and among those with
self-reported calciumintake$921mg/dL
versus,921mg/dL(0.59[0.42–0.82]vs.
0.84 [0.59–1.16]). However, the study
hadinadequatepowertoassessthesignif-
icance of the association within sub-
groups, and the tests for interaction
were not statistically signiﬁcant in any of
the strata analyzed (P for interactions
.0.40) (Table 4).
CONCLUSIONSdIn this unique co-
hort ofU.S.adults at high risk for diabetes,
higher plasma 25-hydroxyvitamin D con-
centrations, assessed repeatedly during the
follow-up period, were associated with
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Vitamin D and diabeteslower risk of diabetes, even after adjust-
ing for weight loss and lifestyle interven-
tions (dietary changes and increased
physical activity) known to decrease di-
abetes risk.
Our results are consistent with those
from other observational longitudinal
studies that have reported on the associ-
ationbetweenvitaminDstatusandriskof
developing type 2 diabetes (7–9,11–
15,35,36). The association between
higher vitamin D levels and lower risk of
type2diabeteswasstatisticallysigniﬁcant
in seven published cohorts (7,9,11–
13,15,36) and was in the same direction,
albeit not statistically signiﬁcant, in three
other cohorts (8,9,35). In one cohort
among older postmenopausal women,
lower serum 25-hydroxyvitamin D was
not associated with increased risk of de-
veloping type 2 diabetes (14).
Ourstudyoffersamethodologicalad-
vantage over previous studies, which
assessed vitamin D status (either by self-
reported total vitamin D intake [7,35],
predicted 25-hydroxyvitamin D score
[11], or blood 25-hydroxyvitamin D con-
centration [9,12–14,36]) based on a sin-
glebaselinemeasurement,whichmaynot
reﬂect long-term vitamin D status. Use of
repeated measurements and cumulative
averages of dietary variables has been
shown to yield stronger associations
than useof asinglebaselinemeasurement
(33), and this was the case in our study.
The need for repeated measurements is
especially true with vitamin D, as single
measurements of 25-hydroxyvitamin D
may not reﬂect vitamin D status over
time, owing to changes in dietary and
other lifestyle changes, weight changes,
sun exposure, and other relevant factors
that may change during follow-up. Mea-
suring 25-hydroxyvitamin D at multiple
time points during follow-up allowed us
to reduce measurement error and obtain
an integrated measure that reﬂects long-
termvitaminDstatusforeachparticipant,
which may be more relevant etiologically
than the most remote (baseline) value
(33). An alternative explanation of our re-
sultsmaybethatplasma25-hydroxyvitamin
D is a marker of the DPP treatment effects
from increased physical activity and
weight loss; however, the association re-
mained after we adjusted for the main ef-
fects of the DPP intervention (changes in
physical activity and weight) during the
study period. Although the analyses ad-
justed for these factors, residual con-
founding cannot be excluded. Our study
hasadditionalstrengths,suchastheinclu-
sion of a large clinically relevant popula-
tion at high risk for diabetes with a
substantialproportionofnonwhitepartic-
ipants, which improves the external valid-
ity of our results because they are directly
applicable to people at risk for diabetes
who are in need for effective interventions
to delay progression to diabetes. Also,
the diagnosis of diabetes was rigorously
evaluated and conﬁrmed based on
repeated laboratory measures, which is
in contrast with other observational
studies that ascertained diabetes by val-
idated self-report (7,8,12,14,35), com-
bination of self-report and laboratory
measurement (11), or registry-based data
(9,36). Furthermore, the method we used
to measure 25-hydroxyvitamin D has
been validated through the NIST vitamin
D quality assurance program (27).
The results from small clinical trials
and post hoc analysesof larger trialsonthe
effect of vitamin D supplementation on
glycemia or incident diabetes have been
inconsistent (16–23,37–39). In these stud-
ies, vitamin D appears to have beneﬁcial
effects only in people at risk for diabetes
(17,20,23), which is consistent with the
ﬁndings of the current study. In contrast,
vitaminDsupplementationappearstohave
no effectamong those withnormal glucose
tolerance, or a very small effect that would
require a very large sample population to
detect (17,18,22,37,39). The studies that
have reported on the effect of vitamin D
supplementation on glycemia in patients
with established type 2 diabetes were un-
derpowered to draw any ﬁrm conclusions.
The hypothesis that vitamin D may be
relevant to prevention of type 2 diabetes is
biologicallyplausible.Bothinsulinresistance
and impaired pancreatic b-cell function
have been reported with vitamin D insuf-
ﬁciency (4). Vitamin D may have a direct
effect mediated by binding of the active
form, 1,25(OH)2D, to the vitamin D
Table 2dRisk for incident diabetes by tertiles of continuous plasma 25-hydroxyvitamin D concentration in the lifestyle and
placebo arms of the DPP
Tertile of 25-hydroxyvitamin D concentration
No. of person-
years
No. of
participants 1 (Lowest) 2 3 (Highest) P value
Number of participants (events) 680 (162) 678 (141) 681 (123)
Plasma 25-hydroxyvitamin D concentration,
median (IQR), ng/mL 5,536.0 2,039 12.8 (10.4–14.9) 20.9 (18.9–22.6) 30.1 (27.0–34.5) d
Model adjusted for age and sex 5,374.0 2,039 1.00 (reference) 0.80 (0.72–0.88) 0.61 (0.50–0.75) ,0.0001
Model adjusted for age, sex, and BMI 5,373.5 2,039 1.00 (reference) 0.86 (0.78–0.95) 0.72 (0.58–0.89) 0.0023
Multivariate model
a 5,272.5 2,002 1.00 (reference) 0.85 (0.76–0.94) 0.70 (0.55–0.88) 0.0024
Multivariate model and calcium intake
b 5,272.0 2,002 1.00 (reference) 0.84 (0.76–0.94) 0.70 (0.55–0.88) 0.0024
Multivariate model and treatment arm
c 5,272.0 2,002 1.00 (reference) 0.86 (0.77–0.95) 0.72 (0.56–0.90) 0.0054
DataareHR(95%CI)unlessotherwiseindicated.Resultsarepresentedfortertilesofplasma25-hydroxyvitaminDconcentrationasthemeanofthevaluesobtainedat
baseline and 6-month visits. HR of diabetes in each of the two highest tertiles was compared with the lowest tertile by extrapolating the per-unit change in estimated
hazard from the multivariate model. Variables measured at multiple time points throughout the study (25-hydroxyvitamin D, BMI, and physical activity) entered the
analyses as time-varying “lagged” covariates, as the mean of the previous and current visits at which diabetes status was assessed. To convert plasma 25-hydrox-
yvitamin D concentration from ng/mL to nmol/L multiply by 2.459.
aAdjusted for recruitment location, age (years), sex (male or female), BMI (kg/m
2), race (black,
white, or other), family history of diabetes (yes or no), personal history of hypertension at baseline (yes or no), smoking status at baseline (never, past, or currently
smoking),alcoholconsumption(average ofvaluesself-reportedat baselineand 1-year follow-upvisits, g/day), C-reactiveprotein (average ofvalues at baselineand6-
month and 1-year follow-up visits, mg/L), kidney function (average of estimated glomerular ﬁltration rate at baseline and 6-month and 1-year follow-up visits, mL/
min/1.73m
2),andself-reportedphysicalactivity(MET-hoursperweek).
bAdjustedforeverythinginﬁrstfootnotepluscalciumintake(averageofvaluesself-reported
at baseline and 1-year follow-up visits, mg/day).
cAdjusted for everything in second footnote plus treatment arm (intensive lifestyle or placebo).
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Pittas and Associatesreceptor expressed in pancreatic b-cells.
The presence of the vitamin D response
element in the human insulin gene pro-
moter and transcriptional activation of the
humaninsulingenecausedby1,25(OH)2D
further support a direct effect of vitamin
D on insulin synthesis and secretion. Fi-
nally, activation of vitamin D may occur
within the b-cell by 25-OHD-1a-
hydroxylase (CYP27B1), which is ex-
pressed in b-cells.
Although 25-hydroxyvitamin D is a
well-established biomarker of exposure
for vitamin D due to intake or biosynthe-
sis, there is a lack of clarity regarding the
validity of 25-hydroxyvitamin D as a
marker of biological effects (24). The
2011 IOM Dietary Reference Intakes for
Calcium and Vitamin D report concluded
that adequate evidence for setting dietary
referenceintakesforvitaminDexistsonly
in relation to skeletal outcomes and
recommended a 25-hydroxyvitamin D
level .20 ng/mL as sufﬁcient. For non-
skeletal outcomes, including diabetes,
the IOM report concluded that available
data are inconclusive and therefore
notsufﬁcientfordietaryreferenceintakes
development. The report also noted
that levels .30 ng/mL are not consis-
tently associated with increased beneﬁt,
whereas a level .50 ng/mL may be a
“reasonforconcern.” Ourresultssupport
the hypothesis that higher blood 25-
hydroxyvitamin D (.30 ng/mL) is asso-
ciatedwithlowerriskofdiabetes,andthe
observed inverse association was linear at
all levels of 25-hydroxyvitamin D. Al-
though ourstudyincluded veryfew par-
ticipants with very high ($50 ng/mL)
25-hydroxyvitamin D levels, potentially
limiting interpretation, this group ap-
peared to have the lowest risk of pro-
gressing to diabetes, and our modeling
of vitamin D levels as a continuous linear
variable supports a beneﬁt for this upper
tail of the distribution.
In subgroup analyses, the inverse asso-
ciationsbetweenplasma25-hydroxyvitamin
D and incident diabetes were consistent,
across all subgroups. The association ap-
peared to be stronger among participants
randomizedtoplacebo,thoseolderthan50
years, obese people, women, and those
with higher calcium intake. It is important
to note that the tests for interaction were
not statistically signiﬁcant; therefore,
no ﬁrm conclusions can be drawn from
these subgroup analyses.
Of note, the observed inverse asso-
ciation between vitamin D status and
incident diabetes did not appear to be
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Vitamin D and diabetesaffectedbyrace(asaproxyforthealtered
vitamin D homeostasis in people with
darkskin).These data suggest thatalthough
there are well-recognized differences in
vitamin D metabolism among different
race/ethnicgroups(40),highervitaminD
status is associated with lower risk of di-
abetesamongallpeopleregardlessofskin
color.
In conclusion,higher vitamin D status,
assessed by plasma 25-hydroxyvitamin D
concentration measured repeatedly during
follow-up, was associated with a lower
risk of incident diabetes among people at
highriskforthedisease.Iftheseresultsare
conﬁrmed in ongoing and planned ran-
domized trials ofvitaminD,theywillhave
important public health implications be-
cause both of these interventions can be
implemented easily and inexpensively to
prevent progression of type 2 diabetes
among those at high risk.
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Table 4dRisk for incident diabetes by tertiles of plasma 25-hydroxyvitamin D concentration in the lifestyle and placebo arms
of the DPP by subgroups
Tertiles of 25-hydroxyvitamin D concentration
No. of person-
years
No. of
participants
1
(Lowest) 2
3
(Highest)
P value
for HR
P value for
interaction
Plasma 25-hydroxyvitamin
D concentration, median
(IQR), ng/mL 5,272.0 2,002 12.8 (10.4–14.9) 20.9 (18.9–22.6) 30.1 (27.0–34.5)
By DPP treatment arm 0.6721
Lifestyle only 2,751.0 1,006 1.00 (reference) 0.90 (0.75–1.08) 0.80 (0.54–1.17) 0.2713
Number of participants (events) 304 (46) 349 (49) 353 (43)
Placebo only 2,521.0 996 1.00 (reference) 0.85 (0.74–0.97) 0.70 (0.52–0.94) 0.0201
Number of participants (events) 364 (106) 310 (88) 322 (75)
Baseline age (median, years) 0.6910
,50 2,462.5 956 1.00 (reference) 0.91 (0.77–1.06) 0.81 (0.57–1.12) 0.2190
Number of participants (events) 361 (83) 312 (66) 283 (53)
$50 2,809.5 1,046 1.00 (reference) 0.81 (0.69–0.95) 0.64 (0.46–0.90) 0.0103
Number of participants (events) 307 (69) 347 (71) 392 (65)
Sex 0.5933
Female 3,510.5 1,339 1.00 (reference) 0.83 (0.72–0.96) 0.68 (0.50–0.91) 0.0118
Number of participants (events) 513 (108) 416 (93) 410 (61)
Male 1,761.5 663 1.00 (reference) 0.91 (0.76–1.09) 0.82 (0.55–1.19) 0.3144
Number of participants (events) 155 (44) 243 (44) 265 (57)
Race 0.6266
White 3,044.0 1,143 1.00 (reference) 0.88 (0.76–1.01) 0.76 (0.56–1.02) 0.0737
Number of participants (events) 237 (58) 410 (85) 496 (86)
Nonwhite 2,228.0 859 1.00 (reference) 0.85 (0.70–1.02) 0.71 (0.47–1.04) 0.0892
Number of participants (events) 431 (94) 249 (52) 179 (32)
Baseline BMI (kg/m
2) 0.7666
BMI ,30 1,994.0 735 1.00 (reference) 0.89 (0.72–1.08) 0.78 (0.50–1.18) 0.2475
Number of participants (events) 156 (31) 238 (32) 341 (49)
BMI $30 3,278.0 1,267 1.00 (reference) 0.85 (0.74–0.97) 0.70 (0.52–0.93) 0.0160
Number of participants (events) 512 (121) 421 (105) 334 (69)
Baseline calcium (median, mg/day) 0.4102
,921 2,667.5 1,008 1.00 (reference) 0.92 (0.78–1.07) 0.84 (0.59–1.16) 0.3005
Number of participants (events) 419 (94) 300 (59) 289 (56)
$921 2,604.5 994 1.00 (reference) 0.78 (0.66–0.91) 0.59 (0.42–0.82) 0.0020
Number of participants (events) 249 (58) 359 (78) 386 (62)
DataareHR(95%CI)unlessotherwiseindicated.Resultsarepresentedfortertilesofplasma25-hydroxyvitaminDconcentration,asthemeanofthevaluesobtainedat
baseline and 6-month visits. HR of diabetes in each of the two highest tertiles was compared with the lowest tertile by extrapolating the per-unit change in estimated
hazard from the multivariate model. Variables measured at multiple time points throughout the study (25-hydroxyvitamin D, BMI, and physical activity) entered the
analyses as time-varying “lagged” covariates, as the mean of the previous and current visits at which diabetes status was assessed. To convert plasma 25-hydrox-
yvitamin D concentration from ng/mL to nmol/L, multiply by 2.459. Models adjusted for recruitment location, age (years), sex (male or female), BMI (kg/m
2), race
(black, white, or other), family history of diabetes (yes or no), hypertension at baseline (yes or no), smoking status at baseline (never, past, or currently smoking),
alcoholconsumption(averageofvaluesself-reportedatbaselineand1-yearfollow-upvisits,g/day),C-reactiveprotein(averageofvaluesatbaselineand6-monthand
1-yearfollow-upvisits,mg/L),kidneyfunction(averageofestimatedglomerularﬁltrationrateatbaselineand6-monthand1-yearfollow-upvisits,mL/min/1.73m
2),
self-reportedphysicalactivity(MET-hoursperweek),calciumintake(averageofvaluesself-reportedatbaselineand1-yearfollow-upvisits,mg/day).Allanalysesalso
adjusted for DPP treatment arm (intensive lifestyle or placebo), except for analyses by treatment arm.
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